News|Articles|December 1, 2002
Pegasys: Peginterferon alfa-2a
Chronic hepatitis C therapy for patients with compensated liver disease
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
New drug class shows promise for geographic atrophy
2
CMS negotiates a 70% discount for Ozempic and Wegovy
3
Research uncovers ‘master switches’ that could portend Type 1 diabetes
4
Overview of BRAF V600E–Mutant NSCLC and Rationale for Targeted Therapy
5
